Search Clinical Trials in the European Union
Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3521-3540 of 3,900 trials
Intrahepatic CholestasisSafety phase (I)Hepatology
Chronic Lymphocytic Leukemia and Small Cell Lymphocytic Lymphoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology
Vitamin D Insufficiency Related to Tooth Extraction1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOrthopedics and TraumatologyOtolaryngologyPediatrics
Radiologically Isolated Syndrome>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesNeurology
Ulcerative ColitisCrohn's Disease>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine
Type 2 DiabetesMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesDiabetologyEndocrinology
Knee Synovitis and Osteoarthritis≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteOrthopedics and TraumatologyRheumatology
Narcolepsy with CataplexyIdiopathic Hypersomnia3-6 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology
Adrenal Incidentalomas and Mild Cushing’s Syndrome>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesCardiologyEndocrinology
Non-Metastatic Muscle Invasive Bladder Cancer1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesOncologyUrology
Pancreatic Cancer with Peritoneal MetastasesEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology
Generalized Myasthenia Gravis6-12 monthsConfirmation phase (III)Standard MedicinesNeurologyRheumatology
Cardiac Arrest and Ventricular Fibrillation6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine
Normal Heart RhythmNormal Ejection FractionBeta-blocker Use≤3 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCardiologyInternal Medicine
Worsening Heart Failure≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine
Spinocerebellar Ataxia Type 7 (SCA7)1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesInternal MedicineNeurology
Neurotrophic Keratitis≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesOphthalmology
Chronic Graft-Versus-Host Disease>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology